Background: The costs of new treatments for patients with advanced melanoma are high, and national medical expenses may increase.
Methods: We conducted a questionnaire survey about medical expenses for patients with stage II-IV melanoma and compared it by treatment. We compared the medical results in our department in the first half of 2015 with those of the previous year. We also investigated the clinical response, convalescence, and costs of the new treatment in an advanced melanoma patient treated during the period of from September, 2014 to March, 2016.
Results: In the new treatment group medical expenses became higher than 20% of the cost of living, and a feeling of burden was strong. Medical treatment fees, medical treatment unit price, and medical expenses rates increased in comparison with the previous year. The treatments and duration of treatments in 24 patients undergoing the new treatment varied, but the drug costs were always very high.
Conclusions: Dermatologists should understand the medical burdens on patient with advanced melanoma, and the hospital management, as well as the problem of national medical expenses; they should be also aware of the economic issues of new treatments for advanced melanoma.
We retrospectively analyzed 71 cases of rosacea-like dermatitis who had undergone skin testing at our hospital between January 2001 and October 2012. The group included one male and 70 females, and had a median age of 52 years. Approximately 40% of the patients were suspected of having contact dermatitis, but had not undergone skin tests. As a result of the skin tests, we diagnosed 70% of the patients (52 cases) as having allergic contact dermatitis; 32 of those cases were caused by cosmetics. Skin testing is a useful tool for investigating the cause of rosacea-like dermatitis and for deciding on appropriate treatment, because many patients with rosacea-like dermatitis actually have contact dermatitis.